Psychemedics Releases 2025 Workforce Insights Report

Rhea-AI Summary

Psychemedics Corporation (PMD) has released its 2025 Workforce Insights Report, revealing critical trends in workplace drug testing based on analysis of hundreds of thousands of hair samples from 2024. The report highlights several concerning trends: synthetic opioids like fentanyl and nitazenes are increasing, healthcare and manufacturing sectors show the highest positive drug test rates at 14.7% and 14.6% respectively, and states with legalized marijuana reported a 10% rise in workplace injuries among young workers. The report emphasizes hair testing's superiority with a 90-day detection window and strong resistance to evasion. CEO Brian Hullinger emphasizes the growing challenges employers face in maintaining safe workplaces amid evolving drug threats and changing legislation.

Positive

• Hair testing offers superior 90-day detection window and high resistance to evasion
• Company maintains largest proprietary database of hair drug testing results in the industry
• Report provides comprehensive sector-specific insights across multiple industries

Negative

• Healthcare and manufacturing sectors show alarmingly high positive drug test rates of 14.7% and 14.6%
• Increasing detection of dangerous synthetic opioids including ultra-potent nitazenes
• 10% increase in workplace injuries among young workers in states with legalized recreational cannabis

Insights

Workplace Safety Analytics Expert

Psychemedics' report highlights growing drug threats in workplaces, positioning the company strategically in expanding employment screening market.

Psychemedics' 2025 Workforce Insights Report offers compelling market intelligence on the evolving substance abuse landscape facing employers. The report's findings of increased synthetic opioid detection, including ultra-potent nitazenes, signal expanding demand for Psychemedics' specialized testing capabilities. The company leverages its proprietary database of hair testing results to establish thought leadership in the employment screening sector.

The report's sector-specific insights are particularly valuable, identifying healthcare and manufacturing as high-risk industries with positive test rates approaching 15%. This targeted analysis helps Psychemedics appeal to these sectors where testing demand may grow. Additionally, the documented 10% increase in workplace injuries in states with legalized cannabis represents a potential catalyst for expanded testing protocols.

Strategically, this report positions Psychemedics as offering solutions to emerging threats that standard drug panels might miss. By emphasizing hair testing's 90-day detection window versus shorter windows for urine testing, the company differentiates its product in a competitive screening market. The timing aligns with rising employer concerns about workplace safety amid changing drug laws and potency trends.

The release of this comprehensive data demonstrates Psychemedics' commitment to value-added services beyond basic testing, potentially strengthening client relationships and supporting premium pricing strategies. This annual report series helps cement the company's position as an authority in workplace drug screening while highlighting growing market opportunities.

Synthetic Drug Threats and Legalization Risks Shape a New Era for Workplace Safety

DALLAS, June 16, 2025 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair testing for drugs of abuse, today announced the release of its second annual Workforce Insights Report, providing a comprehensive look at the evolving drug landscape and its impact on workplace safety, hiring practices, and employer risk.

The 2025 Psychemedics Insights Report draws from the largest proprietary database of hair drug testing results in the industry, analyzing hundreds of thousands of samples collected in 2024 across a wide range of sectors, including transportation, manufacturing, healthcare, government, and more. The report reveals critical workforce trends and emerging threats employers must navigate in today’s rapidly changing drug climate.

Key findings from the 2025 report include:

• Synthetic opioids on the rise: Fentanyl remains a top concern, with increasing detection of ultra-potent nitazenes, some up to 20x stronger than fentanyl.
• Healthcare and manufacturing industries at highest risk: Positive drug test rates reached 14.7% and 14.6%, respectively.
• Resurgence of cocaine and methamphetamine: Notable increases in stimulant use, particularly in high-pressure industries.
• Legal marijuana and high THC potency: States with legalized recreational cannabis saw a 10% increase in workplace injuries among young workers.
• Hair testing remains the most reliable method, offering a 90-day detection window and unmatched resistance to evasion, making it the gold standard for long-term drug detection.
  

“As the drug landscape evolves, with new synthetic substances, rising marijuana potency, and shifting laws, employers are under growing pressure to maintain safe, compliant, and productive workplaces,” said Brian Hullinger, President and CEO of Psychemedics.

The 2025 report emphasizes the need for comprehensive drug testing strategies that extend beyond detection to include education, prevention, and support. By offering deep insight into five-year trends and sector-specific risks, Psychemedics equips employers with the tools to adapt policies, mitigate liability, and make informed decisions.

The full 2025 Workforce Insights Report is available at: https://www.psychemedics.com/whitepaper/

For more information about Psychemedics Corporation and its innovative hair testing solutions, visit https://www.psychemedics.com.

About Psychemedics 

Psychemedics Corporation is a leading global provider of innovative hair testing for drugs of abuse. With a commitment to accuracy and reliability, the company offers cutting-edge drug testing solutions. Psychemedics Corporation is dedicated to providing valuable insights and maintaining the highest standards in substance abuse testing.

Investor Relations:
Phone: 978-206-8220
Email: InvestorRelations@psychemedics.com

FAQ

What are the key findings of Psychemedics' 2025 Workforce Insights Report?

The report reveals rising synthetic opioid use, high drug test positivity rates in healthcare (14.7%) and manufacturing (14.6%), increased stimulant use, and a 10% rise in workplace injuries among young workers in states with legalized marijuana.

What is the drug detection window for Psychemedics' (PMD) hair testing?

Psychemedics' hair testing offers a 90-day detection window and is noted for being highly resistant to evasion attempts.

Which industries showed the highest positive drug test rates in Psychemedics' 2025 report?

Healthcare and manufacturing industries showed the highest positive drug test rates at 14.7% and 14.6% respectively.

How has marijuana legalization affected workplace safety according to PMD's report?

States with legalized recreational cannabis experienced a 10% increase in workplace injuries among young workers.

What new drug threats were identified in Psychemedics' 2025 report?

The report identified increasing detection of synthetic opioids, particularly fentanyl and ultra-potent nitazenes (up to 20x stronger than fentanyl), along with a resurgence in cocaine and methamphetamine use.